This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2009 Oct;124(4):854-6.

doi: 10.1016/j.jaci.2009.07.051. Epub 2009 Sep 19.

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously

Shilpa H Desai, Akhil Chouksey, John Poll, Melvin Berger

PMID: 19767071
DOI: 10.1016/j.jaci.2009.07.051

Randomized Controlled Trial

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously

Shilpa H Desai et al. J Allergy Clin Immunol. 2009 Oct.

. 2009 Oct;124(4):854-6.

doi: 10.1016/j.jaci.2009.07.051. Epub 2009 Sep 19.

Authors

Shilpa H Desai, Akhil Chouksey, John Poll, Melvin Berger

PMID: 19767071
DOI: 10.1016/j.jaci.2009.07.051

No abstract available

PubMed Disclaimer

Similar articles

[Immunoglobulin therapy of primary humoral immunologic deficiencies].
Bordigoni P. Bordigoni P. Rev Prat. 2007 Oct 15;57(15):1691-8. Rev Prat. 2007. PMID: 18080428 French.
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-Hüber J, Zenker O, Grimbacher B. Jolles S, et al. Clin Immunol. 2011 Oct;141(1):90-102. doi: 10.1016/j.clim.2011.06.002. Epub 2011 Jun 12. Clin Immunol. 2011. PMID: 21705277 Clinical Trial.
Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin.
Danieli MG, Gelardi C, Pedini V, Gabrielli A. Danieli MG, et al. Isr Med Assoc J. 2018 Dec;20(12):782-783. Isr Med Assoc J. 2018. PMID: 30550011 No abstract available.
Practical aspects of immunoglobulin replacement.
Ballow M. Ballow M. Ann Allergy Asthma Immunol. 2017 Oct;119(4):299-303. doi: 10.1016/j.anai.2017.07.020. Ann Allergy Asthma Immunol. 2017. PMID: 28958372 Review. No abstract available.
Subcutaneous IgG in the Myositis Spectrum Disorders.
Danieli MG, Gelardi C, Pedini V, Logullo F, Gabrielli A. Danieli MG, et al. Curr Rheumatol Rev. 2018;14(3):194-199. doi: 10.2174/1573397113666170314120602. Curr Rheumatol Rev. 2018. PMID: 28292255 Review.

See all similar articles

Cited by

Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA. Wasserman RL, et al. Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21553933 Clinical Trial.
Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.
Berger M. Berger M. J Clin Immunol. 2011 Oct;31(5):924-6. doi: 10.1007/s10875-011-9546-2. Epub 2011 Jun 4. J Clin Immunol. 2011. PMID: 21643892
Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.
Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, Trizzino A, Baldassarre M, Paganelli R, Moschese V, Soresina A, Matucci A. Vultaggio A, et al. Clin Drug Investig. 2015 Mar;35(3):179-85. doi: 10.1007/s40261-015-0270-1. Clin Drug Investig. 2015. PMID: 25672929 Free PMC article.
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
Grigoriadou S, Clubbe R, Garcez T, Huissoon A, Grosse-Kreul D, Jolles S, Henderson K, Edmonds J, Lowe D, Bethune C. Grigoriadou S, et al. Clin Exp Immunol. 2022 Oct 21;210(1):1-13. doi: 10.1093/cei/uxac070. Clin Exp Immunol. 2022. PMID: 35924867 Free PMC article.
Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C, Duong R, Gruenemeier P, Ernst C, Kitsen J, Geng B. Anterasian C, et al. J Clin Immunol. 2019 Nov;39(8):814-822. doi: 10.1007/s10875-019-00705-5. Epub 2019 Nov 1. J Clin Immunol. 2019. PMID: 31673923 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov